These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 33441310)
1. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310 [TBL] [Abstract][Full Text] [Related]
2. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031 [TBL] [Abstract][Full Text] [Related]
3. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C Gynecol Oncol; 2024 Jul; 186():42-52. PubMed ID: 38582027 [TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
5. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667 [TBL] [Abstract][Full Text] [Related]
6. Advances in precision therapy of low-grade serous ovarian cancer: A review. Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365 [TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. McNamara B; Demirkiran C; Hartwich TMP; Bellone S; Manavella D; Mutlu L; Greenman M; Zipponi M; Yang-Hartwich Y; Yang K; Ratner E; Schwartz PE; Coma S; Pachter JA; Santin AD Gynecol Oncol; 2024 Apr; 183():133-140. PubMed ID: 38493021 [TBL] [Abstract][Full Text] [Related]
8. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952 [TBL] [Abstract][Full Text] [Related]
11. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687 [TBL] [Abstract][Full Text] [Related]
13. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity. Hong A; Piva M; Liu S; Hugo W; Lomeli SH; Zoete V; Randolph CE; Yang Z; Wang Y; Lee JJ; Lo SJ; Sun L; Vega-Crespo A; Garcia AJ; Shackelford DB; Dubinett SM; Scumpia PO; Byrum SD; Tackett AJ; Donahue TR; Michielin O; Holmen SL; Ribas A; Moriceau G; Lo RS Cancer Discov; 2021 Mar; 11(3):714-735. PubMed ID: 33318037 [TBL] [Abstract][Full Text] [Related]
14. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target. Fernandez ML; Dawson A; Hoenisch J; Kim H; Bamford S; Salamanca C; DiMattia G; Shepherd T; Cremona M; Hennessy B; Anderson S; Volik S; Collins CC; Huntsman DG; Carey MS Cancer Cell Int; 2019; 19():10. PubMed ID: 30636931 [TBL] [Abstract][Full Text] [Related]
15. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Thomson JP; Hollis RL; van Baal J; Ilenkovan N; Churchman M; van de Vijver K; Dijk F; Meynert AM; Bartos C; Rye T; Croy I; Diana P; van Gent M; Creedon H; Nirsimloo R; Nussey F; Lok C; Herrington CS; Gourley C Gynecol Oncol; 2023 Jul; 174():157-166. PubMed ID: 37207500 [TBL] [Abstract][Full Text] [Related]
16. Low-grade Serous Tumors: Are We Making Progress? Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304 [TBL] [Abstract][Full Text] [Related]
17. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum. Grisham RN; Chui MH Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920 [TBL] [Abstract][Full Text] [Related]
18. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169 [TBL] [Abstract][Full Text] [Related]
19. mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population. Jordan SE; Saad H; Covarrubias AS; Siemon J; Pearson JM; Slomovitz BM; Huang M; Pinto A; Schlumbrecht M; George SH Gynecol Oncol; 2020 Nov; 159(2):554-562. PubMed ID: 32951896 [TBL] [Abstract][Full Text] [Related]